Who founded Barricade Therapeutics?

Barricade Therapeutics was founded by Neil C. Thapar, John Walling.

Who are Barricade Therapeutics's investors?

Barricade Therapeutics's investors include Green Park & Golf Ventures.

How much funding has Barricade Therapeutics raised?

Barricade Therapeutics has disclosed $100K raised across 1 round.

Where is Barricade Therapeutics headquartered?

Barricade Therapeutics is headquartered in Fort Worth, US.

Barricade Therapeutics

Fort Worth, US · Delaware corporation · 1 known investors

Find your way into Barricade Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Barricade Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Barricade Therapeutics is a biotech company focused on oncology drug development, working to advance cancer treatments through evidence-based clinical pharmacology.

Biotech Healthtech

Founders & leadership

Neil C. Thapar Co-Founder, Board Chairman, CEO & Chief Scientific OfficerNeil C. Thapar is co-founder, board chairman, CEO, and chief scientific officer of Barricade Therapeutics, a biotech company developing cancer treatments. He has extensive background in drug development, clinical pharmacology, pharmacokinetic modeling, and analytical chemistry methods across preclinical and clinical stages.

John Walling Co-Founder, SVP, CMCHe has prior experience in pharmaceutical development, including active pharmaceutical ingredient formulation, solid oral and parenteral drug product development, and CMC regulatory strategy for IND, NDA, and marketing authorization filings.

Mariam E. MorrisChief Operating Officer

Scott JordanChief Financial Officer

Investors · 1

Green Park & Golf Ventureslisted by Green Park & Golf VenturesDallas · $500K – $2M

How we know: Green Park & Golf Ventures's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$100K disclosed across 1 round · 2026

▶$100KraisedJun 2026 · 1 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Neil ThaparExecutive Officer

Amount sold: $100K
First sale: May 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 6

Bicara TherapeuticsBicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors. The company's lead program, ficerafusp alfa, fuses an EGFR-directed antibody with a TGF-β ligand trap to simultaneously inhibit tumor cell growth and suppress immunosuppressive signaling in the tumor microenvironment, with initial development focused on head and neck squamous cell carcinoma.

Cybrexa, Inc.Cybrexa is a biotechnology company developing cancer therapeutics that use its alphalex peptide-drug conjugate platform to target the low-pH tumor microenvironment for selective delivery. The technology aims to enable more potent drugs and combination therapies and to expand the efficacy of existing anticancer agents.

Parabilis MedicinesHelicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.

Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.

BicycleBicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.

ObsidiantxObsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.

Companies working in the same space as Barricade Therapeutics.

Frequently asked questions

What does Barricade Therapeutics do?: Barricade Therapeutics is a biotech company focused on oncology drug development, working to advance cancer treatments through evidence-based clinical pharmacology.
Who founded Barricade Therapeutics?: Barricade Therapeutics was founded by Neil C. Thapar, John Walling.
Who are Barricade Therapeutics's investors?: Barricade Therapeutics's investors include Green Park & Golf Ventures.
How much funding has Barricade Therapeutics raised?: Barricade Therapeutics has disclosed $100K raised across 1 round.
Where is Barricade Therapeutics headquartered?: Barricade Therapeutics is headquartered in Fort Worth, US.